Vigil Neuroscience (NASDAQ:VIGL) Given “Buy” Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Vigil Neuroscience (NASDAQ:VIGL) in a research note issued to investors on Friday,Benzinga reports. HC Wainwright currently has a $17.00 target price on the stock.

A number of other equities research analysts also recently weighed in on the company. Guggenheim cut their target price on Vigil Neuroscience from $17.00 to $16.00 and set a “buy” rating for the company in a research report on Wednesday, August 14th. Wedbush reiterated an “outperform” rating and set a $23.00 price objective on shares of Vigil Neuroscience in a research report on Thursday, July 11th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $16.80.

Vigil Neuroscience Stock Performance

Shares of VIGL remained flat at $3.57 during midday trading on Friday. The company’s stock had a trading volume of 47,893 shares, compared to its average volume of 236,640. The company’s fifty day moving average is $3.58 and its 200-day moving average is $3.63. The stock has a market capitalization of $141.54 million, a P/E ratio of -1.68 and a beta of 1.92. Vigil Neuroscience has a 12 month low of $2.47 and a 12 month high of $6.98.

Vigil Neuroscience (NASDAQ:VIGL) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.02. Analysts anticipate that Vigil Neuroscience will post -2.15 EPS for the current year.

Institutional Trading of Vigil Neuroscience

Several large investors have recently added to or reduced their stakes in the company. Acadian Asset Management LLC acquired a new stake in Vigil Neuroscience during the 2nd quarter valued at $26,000. Renaissance Technologies LLC increased its position in Vigil Neuroscience by 19.2% during the second quarter. Renaissance Technologies LLC now owns 71,500 shares of the company’s stock worth $286,000 after buying an additional 11,536 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in Vigil Neuroscience during the second quarter worth $87,000. Vanguard Group Inc. increased its position in Vigil Neuroscience by 11.9% during the first quarter. Vanguard Group Inc. now owns 894,473 shares of the company’s stock worth $3,050,000 after buying an additional 95,276 shares during the last quarter. Finally, Ensign Peak Advisors Inc increased its position in Vigil Neuroscience by 72.8% during the second quarter. Ensign Peak Advisors Inc now owns 395,116 shares of the company’s stock worth $1,580,000 after buying an additional 166,442 shares during the last quarter. 83.64% of the stock is owned by institutional investors and hedge funds.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.